BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 8301131)

  • 21. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.
    Plautz GE; Touhalisky JE; Shu S
    Cell Immunol; 1997 Jun; 178(2):101-7. PubMed ID: 9225000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clonal anergy to staphylococcal enterotoxin B in vivo: selective effects on T cell subsets and lymphokines.
    Baschieri S; Lees RK; Lussow AR; MacDonald HR
    Eur J Immunol; 1993 Oct; 23(10):2661-6. PubMed ID: 8104798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
    Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
    Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exogenous superantigens acutely trigger distinct levels of peripheral T cell tolerance/immunosuppression: dose-response relationship.
    Miethke T; Wahl C; Gaus H; Heeg K; Wagner H
    Eur J Immunol; 1994 Aug; 24(8):1893-902. PubMed ID: 8056049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Superantigens anergize cytokine production but not cytotoxicity in vivo.
    Sundstedt A; Dohlsten M; Hedlund G; Höidén I; Björklund M; Kalland T
    Immunology; 1994 May; 82(1):117-25. PubMed ID: 7913912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transforming growth factor beta 1 costimulated growth and regulatory function of staphylococcal enterotoxin B-responsive CD8+ T cells.
    Rich S; Seelig M; Lee HM; Lin J
    J Immunol; 1995 Jul; 155(2):609-18. PubMed ID: 7608539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effect of staphylococcal enterotoxin B upon the induction of tolerance on peripheral CD4+V beta 8+ and CD8+V beta 8+ T cells.
    Sabapathy TK; Hwang LA; Hui KM
    Cell Immunol; 1994 Oct; 158(1):83-95. PubMed ID: 7916268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of mouse liver natural killer cells and NK1.1(+) T cells by bacterial superantigen-primed Kupffer cells.
    Dobashi H; Seki S; Habu Y; Ohkawa T; Takeshita S; Hiraide H; Sekine I
    Hepatology; 1999 Aug; 30(2):430-6. PubMed ID: 10421651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evolutionary conserved mechanism of T cell activation by microbial toxins. Evidence for different affinities of T cell receptor-toxin interaction.
    Fleischer B; Gerardy-Schahn R; Metzroth B; Carrel S; Gerlach D; Köhler W
    J Immunol; 1991 Jan; 146(1):11-7. PubMed ID: 1670601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unique cytokine production profile of anergic human T cells in SCID-hu mice after staphylococcal enterotoxin B administration.
    Schols D; Jones D; Roncarolo MG
    J Immunol; 1995 Apr; 154(7):3204-12. PubMed ID: 7534791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Staphylococcal enterotoxin B induces an early and transient state of immunosuppression characterized by V beta-unrestricted T cell unresponsiveness and defective antigen-presenting cell functions.
    Muraille E; De Smedt T; Andris F; Pajak B; Armant M; Urbain J; Moser M; Leo O
    J Immunol; 1997 Mar; 158(6):2638-47. PubMed ID: 9058796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superantigen-induced human CD4+ helper/killer T cell phenomenon. Selective induction of Th1 helper/killer T cells and application to tumor immunotherapy.
    Kuge S; Miura Y; Nakamura Y; Mitomi T; Habu S; Nishimura T
    J Immunol; 1995 Feb; 154(4):1777-85. PubMed ID: 7836762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Superantigen-induced anergy in cytotoxic CD8+ T cells.
    Sundstedt A; Höidén I; Hansson J; Hedlund G; Kalland T; Dohlsten M
    J Immunol; 1995 Jun; 154(12):6306-13. PubMed ID: 7759869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superantigen-induced anergy of V beta 8+ CD4+ T cells induces functional but non-proliferative T cells in vivo.
    Gaus H; Miethke T; Wagner H; Heeg K
    Immunology; 1994 Nov; 83(3):333-40. PubMed ID: 7835956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
    Anderson PM; Blazar BR; Bach FH; Ochoa AC
    J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S; Rosenberg SA
    J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The expression of CD4 and CD8 molecules conditions the behavior of V beta + murine thymocytes upon superantigenic challenge.
    Fattorossi A; Baschieri S; Ferlini C; Doria G
    Thymus; 1997; 24(3):133-45. PubMed ID: 9151379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.